NeoGenomics, Inc. $NEO Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its position in NeoGenomics, Inc. (NASDAQ:NEO) by 34.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,133,026 shares of the medical research company’s stock after selling 599,003 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in NeoGenomics were worth $8,407,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Light Asset Management LLC grew its holdings in shares of NeoGenomics by 1.1% during the fourth quarter. First Light Asset Management LLC now owns 10,035,063 shares of the medical research company’s stock worth $118,012,000 after buying an additional 107,794 shares in the last quarter. First Trust Advisors LP acquired a new position in NeoGenomics during the first quarter worth about $45,725,000. Geode Capital Management LLC boosted its position in NeoGenomics by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 3,176,644 shares of the medical research company’s stock worth $37,364,000 after acquiring an additional 44,733 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in NeoGenomics by 9.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock valued at $19,842,000 after acquiring an additional 225,588 shares in the last quarter. Finally, American Capital Management Inc. grew its stake in NeoGenomics by 120.9% during the 3rd quarter. American Capital Management Inc. now owns 2,345,263 shares of the medical research company’s stock valued at $18,105,000 after acquiring an additional 1,283,390 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Stock Performance

NASDAQ:NEO opened at $15.29 on Monday. The company’s 50-day moving average is $12.77 and its two-hundred day moving average is $10.71. NeoGenomics, Inc. has a 1-year low of $4.72 and a 1-year high of $16.17. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.60 and a quick ratio of 3.35. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -38.22 and a beta of 1.74.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.03 by $0.02. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.99%. The firm had revenue of $201.66 million for the quarter, compared to analyst estimates of $196.93 million. During the same quarter in the previous year, the company earned $0.03 EPS. The business’s revenue for the quarter was up 11.2% compared to the same quarter last year. Analysts forecast that NeoGenomics, Inc. will post -0.15 EPS for the current year.

Analyst Upgrades and Downgrades

NEO has been the topic of a number of research reports. TD Cowen reissued a “buy” rating on shares of NeoGenomics in a research note on Wednesday, July 15th. Benchmark lifted their price objective on NeoGenomics from $11.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Needham & Company LLC boosted their price objective on NeoGenomics from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Leerink Partners upgraded NeoGenomics from a “market perform” rating to an “outperform” rating and upped their target price for the company from $12.00 to $25.00 in a report on Wednesday, April 29th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.71.

Insider Transactions at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the firm’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total transaction of $59,916.03. Following the completion of the sale, the director owned 91,422 shares of the company’s stock, valued at $1,032,154.38. This trade represents a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.10% of the stock is currently owned by company insiders.

NeoGenomics Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.